StockData
Vicapsys Life Sciences, Inc. logo

Vicapsys Life Sciences, Inc. (VICP) shareholders

VICPOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2024, quý kết thúc ngày Sep 30, 2024Last filing: 10-Q on Jan 10, 2025
$0.40+0.00 (0.00%)

Close on Oct 19, 2026Market cap $13.73MP/E –Yield –

Ownership

Who owns Vicapsys Life Sciences's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Wildcat Capital Management, LLC
Joint filing with Wildcat Partner Holdings, LP (18.80%), Leonard A. Potter (18.80%)
6,070,58818.80%13G (passive)Apr 20, 2020

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Leonard Potter10% owner6,070,58818.75%Mar 21, 2025
Wildcat Partner Holdings, LP10% owner––Mar 21, 2025
Wildcat Capital Management, LLC10% owner––Mar 21, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Michael Yurkowski
Director
Sep 3, 2010Sale−5,000$0.15$750760,000
Michael Yurkowski
Director
Aug 9, 2010Sale−20,000$0.20$4.00K765,000
Michael Yurkowski
Director
Jan 26, 2010Award−5,000$0.60$3.00K785,000
Michael Yurkowski
Director
Jan 14, 2010Sale−5,000$0.50$2.50K790,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
0.0%
From 0M shares
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vicapsys Life Sciences's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?